Presenter's Information

Renu Virmani, MD

Country USA
Specialty Interventional Cardiologist
  1. Vulnerable Plaque: What Is It? Pathological Perspective
  2. Pathologic Perspective
  3. DCB Versus DES for SFA: Which Is Better?
  4. Pathology of TAVR and Mitral Devices
  5. Not All DCBs Are Created Equal: Side by Side Pre-clinical Safety Evaluation of Leading DCBs
  6. DES Failure: Pathologic Findings and Treatment
  7. No, It is Not Yet Ready.
  8. Natural History of Vulnerable Plaque: Targets for Risk Stratification
  9. Unique Demands of the Femoral Anatomy and Pathology and the Need for Unique Interventions
  10. Autopsy Studies of TAVR - What Have We Learnt?
  11. Late Complication: Stent Fractures and Restenosis
  12. Pathology of Transcatheter Aortic Valve Implantation
  13. Pathogenesis of Vulnerable Plaque 2013: What's New?
  14. Thrombosis and Inflammation in Plaque Vulnerability: What Is the Next Target for New Drugs?
  15. Vulnerable Plaque: Anatomic Features Linked to Future Events
  16. Plaque Progression and Instability: Critical Insights from Pathology
  17. Neoatherosclerosis: Correlates OCT/IVUS with Histology
  18. Histolopathologic Validation of In-stent Neoatherosclerosis
  19. Mechanisms of Plaque Destabilization: Pathologic Observation
  20. Evidence and Future Perspective for Vulnerable Plaque from Pathologic Data
  21. Evolving Pathologic Perspectives on the Etiology of AMI
  22. DES Pathobiology: Insights from Assessment of Endothelial Integrity and Function
  23. Why Even Favorable One-Year Data From HORIZONS Shouldn’t Compel DES Usage in AMI
  24. Characterizing the Vulnerable Plaque: Structural Observations and Natural History Insights from the Core Pathology Laboratory
  25. Next Generation DES: Results from Preclinical Data
  26. DES Pathology Update - What We Know, What We Do Not Know
  27. Why Current DES Should NOT be Used Routinely During Primary AMI Angioplasty!
  28. The Causes of Late DES Thrombosis: a Pathologist's Viewpoint!
  29. New Pathologic Insights into Vulnerable Plaques
  30. Erosion, Intraplaque Hemorrhage: The Other Face of Vulnerability
  31. Pathology of Vulnerable Plaque
  32. DES Pathobiology Considerations: What We Know and What We Don't Know Can Hurt Us!
  33. The Value of Animal Models in Evaluating Pathobiologic Effects of Drug-Eluting Stents: Insights from Past Successes and Failures
  34. Should We Expect "Late Catch-up"(Late Restenosis) After DES Treatment-Is the Genie Already out of the Bottle? You Have Simply Postponed the Inevitable
Conference Slides
Category